CannabisNewsWire
Editorial Coverage: Fueled by an explosion of CBD-infused
edibles, billion-dollar projections for the CBD market may even be
conservative.
This seems possible when one considers the truly innovative work
being done in the sector by the likes of Lexaria Bioscience
Corp. (CSE: LXX) (OTCQX: LXRP) (LXRP
Profile), which has developed a patented delivery
technology with disruptive potential, delivering 475%
more CBD to the bloodstream after 15 minutes than conventional
formulations. Other sector innovators are making a similar impact,
including the likes of noted cannabinoid biopharma GW
Pharmaceuticals Plc (NASDAQ: GWPH) (OTC: GWPRF) and that
of researchers and product developers Tilray Inc. (NASDAQ:
TLRY), MariMed Inc. (OTCQB: MRMD) and
Aurora Cannabis Inc. (TSX: ACB) (NYSE: ACB).
- CBD is going mainstream into all kinds of consumer goods and
foodstuffs.
- Hard data on numerous health benefits appears to be core driver
behind growing CBD acceptance.
- $1 billion-plus cannabis edibles segment growing rapidly but
separate from CBD market.
- Innovative delivery tech could revolutionize the industry and
consumer receptivity.
To view an infographic of this editorial, click here.
Mainstream CBD Teeing Up an Edibles Boom
The recent May 9 report from leading cannabis industry analysts
BDS Analytics and Arcview Market Research forecasts that the market
for nonpsychoactive cannabinoid CBD (cannabidiol) alone will
hit upwards of $20 billion by 2024, running at
a CAGR around 49%. With last year’s farm bill legalizing industrial
hemp in the United States, CBD sales in dispensaries have been
rapidly increasing. Additionally fueled by an explosion of
CBD-infused edibles, it appears that conservative
sector growth estimates from analysts such as New York-based
investment bank Cowen & Co. may be shortsighted.
A mounting, positive consumer sentiment about the health
benefits of cannabinoids is broadly underscored by the work of
developers such as GW Pharmaceuticals, whose CBD-based Epidiolex is
already FDA-approved to treat two types of severe childhood
epilepsy. CBD is going mainstream, with high-profile celebrities
such as iconic homemaker Martha Stewart publicly coming out in
support of the numerous health benefits that CBD is said to have,
like lowering stress and anxiety or battling inflammation and pain.
It is little wonder that consumers are seeing CBD used as a nutraceutical additive in everything from
over-the-counter cosmetics and pet health products, to wildly
popular edibles infused with CBD oil.
The cannabis edibles segment is also interesting to many
analysts, and recent forecasts such as the Arcview Group’s $4.1 billion by 2022 figure brings
into stark relief the immense potential of a market that already
ballooned to more than $1 billion last year. BDS Analytics predicts
that the same rapid CBD product sales growth seen at dispensaries
will continue to occur as the majority of sales shift to general
retail stores. An increasingly receptive consumer base is seen
driving this trend, as roughly 66% of hemp-derived CBD consumers in
the United States now believe in full federal legalization of
cannabis in general.
The demand for CBD products now appears to be nothing short of
historic, with CPG (consumer packaged goods) companies having never
witnessed such an insatiable appetite for a new
product type before. CBD, THC and others of the 100 or more
cannabinoids found in cannabis appear to show strong potential for
gobbling up market share across massive, vulnerable consumables
industries, ranging from soft drinks and snack foods to alcoholic
beverages and pet aides.
Revolutionary Delivery Technology Could Supercharge
Edibles Industry
Unfortunately, the vast majority of edible CBD is being
delivered to the human body in an inefficient manner, with most of
the CBD simply ending up in the toilet. Typical CBD-infused
products utilize industry-standard delivery methods such as MCTs
(medium-chain triglyceride) like coconut oil. Such MCTs are a
somewhat crude but straightforward approach, offering a rich
texture and “mouth feel” but promising only limited delivery of
CBD. Lexaria
Bioscience Corp. (CSE: LXX) (OTCQX: LXRP)
DehydraTECH(TM) patented formulations have considerable disruptive
potential amid the ongoing CBD boom, with recent multi-objective
animal studies showing a clear advantage over
industry standards, in terms of how efficiently edible forms of
cannabinoids enter the bloodstream.
The company’s standard DehydraTECH
formulation using LCFAs (long-chain fatty acids) went
head-to-head with a concentration-matched MCT formulation in the
recently announced animal studies, yielding a
whopping 475% higher CBD blood concentration level — and at four
times the speed (15 minutes). These days, it is not uncommon to see
people throwing around terms such revolutionary or
groundbreaking willy-nilly. So when a technology comes
along that truly does represent a fundamental paradigm shift, it
can easily get lost in the ceaseless 24-hour news cycle
cacophony.
Those words may truly apply here. Lexaria’s patented LCFA
formulation has demonstrated a stunning 334% higher average maximum
CBD blood concentration level over a 60-minute interval than
standard MCT oil formulation, with initial onset (measurable CBD in
blood) occurring three times faster (as little as only two
minutes), a key factor for edibles.
This animal-study data is compelling and establishes a solid
foundation under LXRP’s value proposition to investors. That
proposition become even more interesting considering that LXRP is
the only company in the United States with such a powerful
absorption and delivery technology backed up by proven claims in
lab, animal and even human clinical studies. DehydraTECH appears to
deliver more CBD, more quickly, than virtually any other brand or
technology available in the country.
In a recent human clinical study conducted at a medical research
university, DehydraTECH-enabled capsules branded as TurboCBD
delivered 317% more CBD into the human bloodstream than did generic
CBD lacking this impressive technology. Seemingly, the human
testing in addition to animal reinforces the notion that the
industry may be witnessing a revolutionary breakthrough.
No Brag, Just Facts
Consider what this technology could mean for the CBD edibles
space. At 15 minutes, the DehydraTECH formulation achieved 475%
higher concentrations and to levels not seen or achieved by MCT.
This puts DehydraTECH on par with inhalation in terms of how fast
acting it is, something which has been a brass ring to the edibles
industry for many years.
Rapid uptake by the body’s various tissue systems as opposed to
valuable raw ingredients being flushed down the toilet because of
minimal absorption — that is a huge selling point to consumers. And
DehydraTECH technology provides the additional benefit of enabling
lower drug-dosage quantities, an important point to consider given
that “Lexaria has every reason to believe that virtually identical
results would have been achieved if THC was instead the cannabinoid
under examination [in the aforementioned animal studies],
consistent with subjective human clinical studies Lexaria’s
partners have conducted with edible THC products.”
Another great feature of LXRP’s proprietary technology is that
it eliminates bad tastes typically found in CBD oils, thus
eliminating the need for large quantities of sugar or artificial
sweeteners to mask the taste, making the ingredient even more
attractive to health-conscious consumers.
CBD Companies Leading the Charge
Cannabis is going mainstream, with CBD appearing to lead the
way.
GW Pharmaceuticals Plc (NASDAQ: GWPH) (OTC:
GWPRF) has the enviable distinction of developing
Epidiolex, one of the most widely known CBD indications ever
devised. Made world famous by coverage of the drug’s use in
combatting severe childhood epilepsy, the drug is the first
prescription, FDA-approved, plant-derived cannabinoid medicine in
the United States and has acted as a kind brand ambassador for CBD
in general.
Tilray Inc. (NASDAQ: TLRY) has grown into quite
an operation, with a presence in eight countries across four
continents, and worldwide production capacity that is on track to
hit 1.3 million square feet this year. A strategic partnership with
Authentic Brands Group is expected to have co-branded CBD products
hitting consumers throughout ABG’s vast North American distribution
network in the second half of this year. And Tilray even managed to
beat first-quarter sales expectations, having posted a 195% jump in year-over-year revenues to $23
million, on the strength of factors such as solid hemp-food sales
growth from the recently acquired Manitoba Harvest.
MariMed Inc. (OTCQB: MRMD) recently announced the formation of a wholly owned subsidiary
to be entirely focused on hemp-derived CBD products. MariMed Hemp
Inc. will have its own dedicated executive team, proprietary brand
and product lines, as well as distribution and marketing
relationships. A bold move for this multistate operator of licensed
cannabis facilities, which has an increasingly strong presence in
branded cannabis and hemp product lines, as well as a retained
initial core business providing advisory services.
Aurora Cannabis Inc. (TSX: ACB) (NYSE: ACB)
recently made a huge
announcement with entry into a multiyear, multimillion-dollar
agreement with mixed martial arts organization UFC to conduct
hemp-derived CBD research on athlete recovery and wellness at UFC’s
substantial Las Vegas institute site. This high-profile and
well-capitalized initiative could pave the way for sweeping
clinical studies to more thoroughly evaluate CBD across the gamut
of current major target indications such as pain management,
inflammation, injury/exercise recovery and mental well-being.
Lexaria’s DehydraTECH continues to offer hardline absorption
data that makes it one of the most exciting names in CBD delivery
technology today. As the CBD industry continues to build momentum
approaching widespread, mainstream acceptance and inevitable
incorporation into a multiplicity of everyday consumers products
and foods, LXRP stands poised to profit mightily.
For more information on Lexaria Bioscience Corp., visit Lexaria
Bioscience Corp. (CSE: LXX) (OTCQX: LXRP)
About CannabisNewsWire
CannabisNewsWire (CNW) is an information service that provides
(1) access to our news aggregation and syndication servers, (2)
CannabisNewsBreaks that summarize
corporate news and information, (3) enhanced press release
services, (4) social media distribution and optimization services,
and (5) a full array of corporate communication solutions. As a
multifaceted financial news and content distribution company with
an extensive team of contributing journalists and writers, CNW is
uniquely positioned to best serve private and public companies that
desire to reach a wide audience of investors, consumers,
journalists and the general public. CNW has an ever-growing
distribution network of more than 5,000 key syndication outlets
across the country. By cutting through the overload of information
in today’s market, CNW brings its clients unparalleled visibility,
recognition and brand awareness. CNW is where news, content and
information converge.
Receive Text Alerts
from CannabisNewsWire: Text "Cannabis" to
21000
For more information please visit https://www.CannabisNewsWire.com and
or https://CannabisNewsWire.News
Please see full terms of use and disclaimers on the
CannabisNewsWire website applicable to all content provided by CNW,
wherever published or re-published: http://CNW.fm/Disclaimer
CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com
DISCLAIMER: CannabisNewsWire (CNW) is the source of the Article
and content set forth above. References to any issuer other than
the profiled issuer are intended solely to identify industry
participants and do not constitute an endorsement of any issuer and
do not constitute a comparison to the profiled issuer. The
commentary, views and opinions expressed in this release by CNW are
solely those of CNW. Readers of this Article and content agree that
they cannot and will not seek to hold liable CNW for any investment
decisions by their readers or subscribers. CNW is a news
dissemination and financial marketing solutions provider and is NOT
registered broker-dealers/analysts/investment advisers, hold no
investment licenses and may NOT sell, offer to sell or offer to buy
any security.
The Article and content related to the profiled company
represent the personal and subjective views of the Author, and are
subject to change at any time without notice. The information
provided in the Article and the content has been obtained from
sources which the Author believes to be reliable. However, the
Author has not independently verified or otherwise investigated all
such information. None of the Author, CNW, or any of their
respective affiliates, guarantee the accuracy or completeness of
any such information. This Article and content are not, and should
not be regarded as investment advice or as a recommendation
regarding any particular security or course of action; readers are
strongly urged to speak with their own investment advisor and
review all of the profiled issuer’s filings made with the
Securities and Exchange Commission before making any investment
decisions and should understand the risks associated with an
investment in the profiled issuer’s securities, including, but not
limited to, the complete loss of your investment.
CNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E the Securities Exchange Act of 1934, as amended and
such forward-looking statements are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. “Forward-looking statements” describe future expectations,
plans, results, or strategies and are generally preceded by words
such as “may”, “future”, “plan” or “planned”, “will” or “should”,
“expected,” “anticipates”, “draft”, “eventually” or “projected”.
You are cautioned that such statements are subject to a multitude
of risks and uncertainties that could cause future circumstances,
events, or results to differ materially from those projected in the
forward-looking statements, including the risks that actual results
may differ materially from those projected in the forward-looking
statements as a result of various factors, and other risks
identified in a company’s annual report on Form 10-K or 10-KSB and
other filings made by such company with the Securities and Exchange
Commission. You should consider these factors in evaluating the
forward-looking statements included herein, and not place undue
reliance on such statements. The forward-looking statements in this
release are made as of the date hereof and CNW undertakes no
obligation to update such statements.
Source:
CannabisNewsWire
Contact:
CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net
Lexaria Bioscience (CSE:LXX)
Historical Stock Chart
From Dec 2024 to Jan 2025
Lexaria Bioscience (CSE:LXX)
Historical Stock Chart
From Jan 2024 to Jan 2025
